Enfortumab Vedotin Plus Pembro Boosts Survival in Key Groups With Bladder Cancer Before and After Surgery, Phase 3 Study Finds

Topline results, to be presented at an upcoming congress, show enfortumab vedotin and pembrolizumab significantly improve survival for muscle-invasive bladder cancer patients ineligible for cisplatin.